Reply to Olschewski et al.: TMEM16A Potentiation: Possible Drawbacks
Open Access
- 15 September 2020
- journal article
- letter
- Published by American Thoracic Society in American Journal of Respiratory and Critical Care Medicine
- Vol. 202 (6), 905-906
- https://doi.org/10.1164/rccm.202004-1214le
Abstract
No abstract availableThis publication has 5 references indexed in Scilit:
- TMEM16A Potentiation: A Novel Therapeutic Approach for the Treatment of Cystic FibrosisAmerican Journal of Respiratory and Critical Care Medicine, 2020
- Smooth muscle-specific TMEM16A expression protects against angiotensin II-induced cerebrovascular remodeling via suppressing extracellular matrix depositionJournal of Molecular and Cellular Cardiology, 2019
- Targeting TMEM16A to reverse vasoconstriction and remodelling in idiopathic pulmonary arterial hypertensionEuropean Respiratory Journal, 2019
- Mechanosensitive ATP Release Maintains Proper Mucus Hydration of AirwaysScience Signaling, 2013
- Pitfalls of Drug Development: Lessons Learned from Trials of Denufosol in Cystic FibrosisThe Journal of Pediatrics, 2013